Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Incrementally Positive on CMS News
AMAG Hot Sheet
Rating Summary:5 Buy, 5 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 24 | Down: 13 | New: 29
Baird reiterates an Outperform rating on AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) $60 price target.
Baird analyst says, "We are incrementally positive on AMAG shares on the news that CMS has assigned Feraheme with two temporary Q-codes effective 2010, removing meaningful reimbursement lead-time and administrative costs for physicians and providers. In that we had assumed Feraheme would still be reimbursed under miscellaneous codes for 2010, this constitutes upside, giving us increasing confidence in our 2010 Feraheme revenue estimate of $107M.
"No change to estimates. We continue to model 2010 Feraheme revenue of $107M, inferring a fairly steep Q-Q trajectory going forward. This news gives us increasing confidence in this number, now that a key objection has been taken off the table. We remain aggressive buyers."
To see more analyst ratings on AMAG Click Here.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan.
Baird analyst says, "We are incrementally positive on AMAG shares on the news that CMS has assigned Feraheme with two temporary Q-codes effective 2010, removing meaningful reimbursement lead-time and administrative costs for physicians and providers. In that we had assumed Feraheme would still be reimbursed under miscellaneous codes for 2010, this constitutes upside, giving us increasing confidence in our 2010 Feraheme revenue estimate of $107M.
"No change to estimates. We continue to model 2010 Feraheme revenue of $107M, inferring a fairly steep Q-Q trajectory going forward. This news gives us increasing confidence in this number, now that a key objection has been taken off the table. We remain aggressive buyers."
To see more analyst ratings on AMAG Click Here.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan.
You May Also Be Interested In
- Wells Fargo Upgrades Enbridge Energy Partners (EEP) to Outperform; Weakness Provides Opportunity
- Barclays Lowers PT and Estimates on Aruba Networks (ARUN); In-line Q3 and Weak Guidance Not Gonna Cut It
- Barclays Q1 Preview on Best Buy (BBY); Continued Caution on Industry and Company Uncertainty
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
